'Generation Y' wants more: 77 per cent say birth control pills are not just about contraception

                  New pill now available in Canada provides
                             additional benefits

    TORONTO, Jan. 20 /CNW/ - Taking "the pill" is not just about pregnancy
prevention, according to a recent survey of Canadian 'Gen Yers' that focused
on oral contraceptives. More than three-quarters of respondents(1) said they
want an oral contraceptive that reduces the symptoms they experience around
the time of their period. A new birth control pill, YAZ(R) launched in Canada
may help alleviate these symptoms.
    Reducing menstrual cramps (66 per cent),(2) having more control over
their monthly cycle (61 per cent)(3) and improving the condition of their skin
(52 per cent)(4) are at the top of 'Generation Ys' wish lists when it comes to
their oral contraceptive. This is just another example of how Generation Y
wants more control over their lives.

    The Hills reality star, gets real

    "As a 'Gen Yer' working in the entertainment industry, I need to be
disciplined," says Lo Bosworth of the hit show, The Hills. "I have to be in
control of my life at all times - especially my health. I need to make sure
I'm taking care of myself so nothing interrupts my day, including the symptoms
that come around that time of the month."

    New low-dose oral contraceptive gives young women more control(5)

    YAZ(R), a new oral birth control option just approved by Health Canada,
is a low-dose oral contraceptive with a shorter monthly hormone-withdrawal
phase compared to other oral contraceptives. Instead of the traditional 21/7
dosing regimen, YAZ(R) has a unique 24/4 regimen - 24 days of active hormone
pills followed by four days of hormone-free pills. The shorter monthly
hormone-withdrawal phase leads to a reduction in hormone-withdrawal symptoms,
such as headaches, cramps and breast tenderness, which are commonly associated
with traditional dosing schedules.
    "The availability of this new low-dose pill provides women with the
benefits of reduced menstrual symptoms," said Dr. Vivien Brown a family
physician on staff at U of T with an expertise in woman's health. "YAZ(R) is
the first oral contraceptive that not only contains a special progestin called
drospirenone (DRSP), but also has a shorter hormone-withdrawal phase."
    DRSP treats acne and counteracts estrogen-induced sodium and water
retention, resulting in less bloating, something that many women experience
during their period.(6)
    YAZ(R) was found to be safe and well tolerated in a controlled trial
involving 1,027 women, who completed 11,480 treatment cycles. As with any
prescription medication, patients have to consult their physician to get a
prescription for YAZ(R).(7)

    About Bayer Inc.

    Bayer Inc. (Bayer) is a Canadian subsidiary of Bayer AG, an international
research-based group with core businesses in health care, crop science, and
innovative materials. Headquartered in Toronto, Ontario, Bayer Inc. operates
the Bayer Group's HealthCare and MaterialScience businesses in Canada. Bayer
Crop Science Inc., headquartered in Calgary, Alberta, operates as a separate
legal entity in Canada. Together, the companies play a vital role in improving
the quality of life for Canadians - producing products that fight diseases,
protecting crops and animals, and developing high-performance materials for
applications in numerous areas of daily life. Canadian Bayer facilities
include the Toronto headquarters and offices in Montréal and Calgary.
    Bayer Inc. has approximately 1,000 employees across Canada and had sales
of over $986 million CDN in 2007. Globally, the Bayer Group had sales of over
32 billion Euro in 2007. Bayer Inc. invested approximately $45 million CDN in
research and development in 2007. Worldwide, the Bayer Group spends the
equivalent of over 2.5 billion Euro in 2007 in R&D.

    Forward-looking statements

    This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in Bayer's public reports which are available
on the Bayer website at www.bayer.com. The company assumes no liability
whatsoever to update these forward-looking statements or to conform them to
future events or developments.

    About the survey

    A total of 1,000 online surveys were completed among Canadian youth aged
16-22 using a random sample of Harris/Decima panel members, as well as a
targeted sample list of 16-17 year olds, also taken at random.
    In a fashion similar to a telephone study, email addresses from the
panels were pulled at random, according to population specifications, in order
to make the study representative of the Canadian population by region. When
contacted to solicit participation, participants had no prior knowledge of the
subject matter of the study. Harris/Decima controls access to the study
through passwords to ensure that respondents can participate only one time.
Subsequent to completion of the study, the data was weighted for region and

    English Video News Release will be available via satellite:

    Tuesday, January 20, 2009 at 13:30 to 13:45
    Wednesday, January 21, 2009 at 10:30 to 10:45

    Anik F2, C-Band, Transponder 3B @111.1 West
    Vertical Polarization, D/L Freq. 3820MHz.
    Audio subcarriers 6.8 left, 6.2 right

    For assistance with the feed please call: 1-800-565-1471

    Visit the Bayer YAZ(R) Online Media Centre for video, images and
background related to this news release. www.bayer.24-4.ca/en.

    (1) Harris Decima survey November 2008
    (2) Harris Decima survey November 2008
    (3) Harris Decima survey November 2008
    (4) Harris Decima survey November 2008
    (5) YAZ Canadian product monograph
    (6) Drospirenone:pharmacology and pharmacokinetics of a unique
        progestogen: Rolf Krattenmacher, Contraception 62 (2000) 29-38
    (7) Bachmann G, Sulak PJ, Sampson-Landers C, et al.Efficacy and safety of
        a low-dose 24-day combined oral contraceptive containing 20 (micro)g
        ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70:191-98

For further information:

For further information: or to arrange an interview, please contact:
Ethan Pigott, Hill & Knowlton Canada, (416) 558-2783,
ethan.pigott@hillandknowlton.ca; Emily Hanft, Bayer Inc., (416) 240-5434,

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890